查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1971377

植物性止血粉市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

Plant-based Hemostat Powder Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (1g, 3g, 5g, Others), By Application (Surgical Wound Care, General Wound Care), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球植物來源止血粉市場預計將從 2025 年的 2.0459 億美元成長到 2031 年的 3.5812 億美元，複合年成長率為 9.78%。

這些可吸收、生物相容性良好的手術輔助劑通常由氧化纖維素和馬鈴薯澱粉等多醣製成，旨在促進自然凝血過程，並控制小動脈、靜脈和毛細血管的出血。推動這一領域發展的主要因素是複雜手術的日益頻繁以及需要手術干預的慢性疾病在全球範圍內日益加重。因此，高效的術中出血管理對於減少併發症至關重要。根據歐洲醫療技術協會（MedTech Europe）的數據，2024年歐洲將進行超過6,300萬例手術，凸顯了對能夠維持手術效率和安全性的醫療技術的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 2.0459億美元
市場規模：2031年 3.5812億美元
複合年成長率：2026-2031年 9.78%
成長最快的細分市場 外科性創傷護理
最大的市場 北美洲

然而，針對這些III類醫療設備的嚴格法規環境，特別是對療效和安全性的要求，對市場成長構成了重大障礙。為滿足複雜的合規標準（例如歐盟醫療設備法規 (EU MDR)），需要提供強力的臨床證據，這提高了准入門檻並延長了核准時間。這種監管負擔可能會顯著延遲新型植物來源止血產品的上市，增加製造商的研發成本，並最終限制這些創新技術應用於醫療產業。

市場促進因素

全球外科手術和創傷事件的日益頻繁是植物來源止血粉市場發展的主要驅動力。隨著醫療機構面臨應對急性創傷和減少擇期手術的雙重壓力，對這些高吸收率和生物相容性止血劑的需求也日益成長。尤其是在大出血的創傷現場，這些止血粉至關重要，因為它們能夠快速脫水並促進血液凝固，並避免了動物性產品固有的病毒感染風險。世界衛生組織（WHO）在2024年6月發布的報告進一步凸顯了這項需求的迫切性：創傷每年導致全球440萬人死亡，凸顯了對有效止血解決方案的巨大需求。此外，擇期手術數量的增加也加劇了這項需求。根據英國國家醫療服務體系（NHS）統計，截至2024年8月，非緊急治療的候診名單已達760萬人，這意味著大量需要手術耗材的手術正在等待進行。

同時，隨著微創手術和機器人手術的日益普及，人們越來越傾向於使用粉末狀止血劑而非傳統的布質止血劑。這些液體止血劑特別適用於腹腔鏡手術環境，因為它們可以透過細小的套管針精準給藥，並能有效處理難以觸及的解剖部位的不規則出血。這種技術上的兼容性正隨著機器人系統的普及而推動市場顯著成長。例如，直覺外科公司在其2024年10月的財報中披露，全球達文西手術的數量年增約18%。這表明，依賴用途廣泛且易於使用的輔助劑（例如植物來源止血粉）的機器人手術平台正被越來越多的醫生所採用。

市場挑戰

嚴格的安全性和有效性監管要求是植物來源止血粉市場發展的主要障礙。由於這些產品通常因其可吸收性和與血液循環系統的直接接觸而被歸類為III類醫療設備，因此必須接受嚴格的生物相容性審查。製造商必須遵守複雜的合規體系，提供全面的臨床驗證，這顯著增加了研發成本並需要投入大量資源。這些財務和營運壓力大幅提高了市場進入門檻，阻礙了中小企業進入市場，並抑制了行業創新步伐。

這些監管障礙的直接後果是產品上市時間明顯延長。根據歐洲醫療技術協會（MedTech Europe）2024年的數據，根據醫療設備法規（MDR），高風險醫療設備獲得認證平均需要約18個月，這主要是由於認證機構的處理能力有限。如此漫長的核准週期延緩了新型止血解決方案在醫療領域的應用，從而限制了製造商的產生收入能力以及及時響應緊急臨床需求的能力。

市場趨勢

內視鏡噴霧輸送系統的專業化進步顯著推動了市場發展，使得在胃腸內視鏡檢查過程中能夠以非侵入性方式應用植物來源粉末成為可能。製造商正在開發基於導管的工具，這些工具可透過標準內視鏡，將多醣粉末直接輸送到胃腸道不規則出血點，克服了機械夾在潮濕和複雜解剖結構中的局限性。這項創新使得息肉切除術和消化性潰瘍的毛細血管出血能夠快速控制，無需進行開放性手術手術或腹腔鏡手術。為了反映該應用領域的成長，Olympus Corporation於2024年3月宣布，其植物來源止血噴霧技術已覆蓋美國49個州，並已交付超過5000套試劑盒，這表明此類液體溶液在胃腸道領域得到了迅速的臨床應用。

同時，隨著醫療專業人員致力於在控制出血的同時降低手術部位感染（SSI）的發生率，將抗菌成分融入植物來源配方的做法也日益普遍。業內相關人員正透過在纖維素和澱粉衍生的粉末中添加生物相容性抗菌劑，開發具有雙重功能的器械——既能促進凝血，又能抑制傷口部位的細菌生長。這一發展直接應對了院內感染日益成長的經濟和臨床影響，並推動了對維持無菌安全標準的輔助產品的需求。世界衛生組織（WHO）強調了這些預防策略的緊迫性，並在2024年11月發布報告稱，到2050年，有效的感染控制措施每年可預防多達82.1萬人死亡。這強烈鼓勵使用能夠主動降低感染風險的止血劑。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：植物性止血粉的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依規格（1克、3克、5克、其他）
    • 依應用領域（外科性創傷護理、一般創傷護理）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美植物性止血粉市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲植物性止血粉市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區植物性止血粉市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲植物性止血粉市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲植物性止血粉市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球植物性止血粉市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Ethicon Inc.
  • Baxter International Inc
  • Becton Dickinson & Co
  • Bioceres SA
  • Grena AS/Norway
  • PlantTec Medical GmbH
  • Starch Medical Inc
  • Theracion Biomedical
  • Singclean Medical
  • Hemostasis, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19031

The Global Plant-based Hemostat Powder Market is projected to expand from USD 204.59 Million in 2025 to USD 358.12 Million by 2031, reflecting a compound annual growth rate of 9.78%. These absorbable, biocompatible surgical adjuncts, typically derived from polysaccharides like oxidized cellulose or potato starch, are engineered to expedite the natural coagulation process and manage arteriolar, venous, and capillary bleeding. A major catalyst for this growth is the increasing frequency of complex surgical operations and the growing global burden of chronic conditions that necessitate surgical intervention, thereby creating a critical need for efficient intraoperative hemorrhage control to reduce complications. Data from MedTech Europe indicates that in 2024, more than 63 million surgical procedures took place across Europe, underscoring the vital demand for medical technologies that uphold procedural efficiency and safety.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 204.59 MIllion
Market Size 2031USD 358.12 MIllion
CAGR 2026-20319.78%
Fastest Growing SegmentSurgical Wound Care
Largest MarketNorth America

However, market growth faces significant obstacles due to the strict regulatory environment governing these Class III medical devices, especially concerning efficacy and safety requirements. The necessity for robust clinical evidence to satisfy complex compliance standards, such as the European Union Medical Device Regulation, establishes high entry barriers and extends approval timeframes. This regulatory weight can substantially postpone the market launch of novel plant-based hemostatic products and escalate development expenses for manufacturers, ultimately restricting the pace at which these innovations become available to the healthcare industry.

Market Driver

The escalating global frequency of surgical procedures and trauma incidents serves as a fundamental driver for the plant-based hemostat powder market. As medical providers encounter increasing pressure to address acute injuries and clear backlogs of elective surgeries, the demand for these absorbable, biocompatible agents has intensified. These powders are particularly indispensable in high-volume trauma scenarios due to their ability to rapidly dehydrate blood and hasten clotting without the viral transmission risks inherent in animal-derived alternatives. Underscoring the magnitude of this need, the World Health Organization reported in June 2024 that injuries cause 4.4 million deaths globally each year, highlighting a vast requirement for effective bleeding control solutions. Furthermore, the volume of pending surgeries exacerbates this demand; according to NHS England, the waiting list for non-emergency treatments hit 7.6 million pathways by August 2024, indicating a substantial pipeline of operations requiring surgical consumables.

Simultaneously, the rising uptake of minimally invasive and robotic surgeries is fueling a preference for powder-based formulations over conventional textile hemostats. These flowable agents are distinctly appropriate for laparoscopic settings, as they can be accurately deployed through narrow trocars to address irregular bleeding on difficult-to-access anatomical surfaces. This technical compatibility is stimulating notable market expansion as robotic systems become more prevalent. For instance, Intuitive Surgical revealed in their October 2024 earnings report that global da Vinci procedures rose by approximately 18% year-over-year, illustrating the growing reach of robotic platforms that depend on versatile, easily applicable adjuncts such as plant-based hemostatic powders.

Market Challenge

Strict regulatory mandates concerning safety and efficacy represent a major hurdle impeding the progress of the plant-based hemostat powder market. Since these products are typically categorized as Class III medical devices due to their absorbable properties and direct contact with the bloodstream, they are subject to intense scrutiny to guarantee biocompatibility. Manufacturers are required to maneuver through intricate compliance systems that necessitate comprehensive clinical proof, a process that substantially drives up development costs and demands significant resource allocation. This financial and operational pressure establishes formidable barriers to entry, often deterring smaller enterprises from joining the market and stifling the rate of innovation within the industry.

The immediate result of these regulatory obstacles is a distinct delay in bringing products to market. Data from MedTech Europe in 2024 highlights that certifying high-risk medical devices under the Medical Device Regulation took an average of nearly 18 months, largely due to capacity limitations among notified bodies. Such extended approval periods stall the debut of new hemostatic solutions in the healthcare arena, thereby constraining manufacturers' capacity to generate income and address pressing clinical requirements in a timely manner.

Market Trends

The advancement of specialized endoscopic spray delivery systems is notably propelling the market forward by facilitating the non-invasive application of plant-based powders during gastrointestinal interventions. Manufacturers are developing catheter-based tools that pass through standard endoscopes to deposit polysaccharide powders directly onto irregular bleeding areas within the GI tract, resolving the shortcomings of mechanical clips in moist, complex anatomies. This innovation permits swift management of capillary bleeding following polypectomies or in peptic ulcers without requiring open or laparoscopic surgery. Confirming the growth of this application, Olympus Corporation announced in March 2024 that its plant-based hemostatic spray technology has been distributed across 49 U.S. states with over 5,000 kits shipped, demonstrating the swift clinical adoption of these flowable solutions in gastroenterology.

At the same time, the integration of antimicrobial qualities into plant-based formulations is becoming increasingly popular as healthcare providers aim to lower surgical site infections (SSIs) while managing hemorrhage. Industry participants are augmenting cellulose and starch-derived powders with biocompatible antimicrobial agents to produce dual-function devices that not only speed up clotting but also prevent bacterial growth at the wound site. This development directly addresses the rising economic and clinical impact of hospital-acquired infections, fueling the demand for adjuncts that uphold sterile safety standards. Emphasizing the urgency of such preventive strategies, the World Health Organization reported in November 2024 that effective infection control measures could prevent up to 821,000 deaths annually by 2050, providing a powerful incentive for the use of hemostats that actively mitigate infection risks.

Key Market Players

  • Ethicon Inc.
  • Baxter International Inc
  • Becton Dickinson & Co
  • Bioceres SA
  • Grena AS/Norway
  • PlantTec Medical GmbH
  • Starch Medical Inc
  • Theracion Biomedical
  • Singclean Medical
  • Hemostasis, LLC

Report Scope

In this report, the Global Plant-based Hemostat Powder Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plant-based Hemostat Powder Market, By Type

  • 1g
  • 3g
  • 5g
  • Others

Plant-based Hemostat Powder Market, By Application

  • Surgical Wound Care
  • General Wound Care

Plant-based Hemostat Powder Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plant-based Hemostat Powder Market.

Available Customizations:

Global Plant-based Hemostat Powder Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plant-based Hemostat Powder Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (1g, 3g, 5g, Others)
    • 5.2.2. By Application (Surgical Wound Care, General Wound Care)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Plant-based Hemostat Powder Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Plant-based Hemostat Powder Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Plant-based Hemostat Powder Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Plant-based Hemostat Powder Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Plant-based Hemostat Powder Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Plant-based Hemostat Powder Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Plant-based Hemostat Powder Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Plant-based Hemostat Powder Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Plant-based Hemostat Powder Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Plant-based Hemostat Powder Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Plant-based Hemostat Powder Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Plant-based Hemostat Powder Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Plant-based Hemostat Powder Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Plant-based Hemostat Powder Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Plant-based Hemostat Powder Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Plant-based Hemostat Powder Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Plant-based Hemostat Powder Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Plant-based Hemostat Powder Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Plant-based Hemostat Powder Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Plant-based Hemostat Powder Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Plant-based Hemostat Powder Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Plant-based Hemostat Powder Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Plant-based Hemostat Powder Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Plant-based Hemostat Powder Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Plant-based Hemostat Powder Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Ethicon Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Baxter International Inc
  • 15.3. Becton Dickinson & Co
  • 15.4. Bioceres SA
  • 15.5. Grena AS/Norway
  • 15.6. PlantTec Medical GmbH
  • 15.7. Starch Medical Inc
  • 15.8. Theracion Biomedical
  • 15.9. Singclean Medical
  • 15.10. Hemostasis, LLC

16. Strategic Recommendations

17. About Us & Disclaimer